Objectives:

1. Review the potential for modulation of non-glycaemic CV risk factors with SGLT-2 inhibitors

2. Determine the association between initiation of SGLT-2 therapy and HF or death in patients with and without CVD.

Session date: 
Friday, March 8, 2019 - 7:30am to 8:30am
Speaker Name: 
Haseeb Saeed, MD
Location: 
NorthShore - Evanston
Evanston, IL 60201
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.